OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
February 14, 2020
The company has said that all three of its operating sites in China started back up on Feb. 12 and that it is closely monitoring the outbreak.
December 12, 2019
According to a consent decree of permanent injunction issued in September 2019, the health and wellness companies must recall and stop distributing products until the companies comply with the Federal Food, Drug, and Cosmetic Act and other requirements included in the consent decree.
September 11, 2019
FDA issued a statement about the importance of reporting adverse events resulting from the use of compounded drugs.
August 29, 2019
While downgrading the impact of nitrosamine impurities on patients, FDA vows to step up investigations for other drug types.
May 30, 2019
The company is voluntarily recalling Amikacin Sulfate Injection, USP, 1g/4 mL (250mg/mL), and Prochlorperazine Edisylate Injection, USP, 10mg/2mL (5mg/mL), to the consumer level because microbial growth was detected.
May 17, 2019
TraceLink will participate in the agency’s Pilot Project Program under the Drug Supply Chain Security Act.
May 03, 2019
The company is recalling one lot of Mycophenolate Mofetil for Injection, USP because of glass fragments found in a vial after reconstitution.
May 02, 2019
The company is recalling one lot of Ketorolac Tromethamine Injection, USP, 60mg/2mL because of a lack of sterility assurance.
April 15, 2019
EMA is evaluating the safety of Lemtrada (alemtuzumab) after new side effects were reported.
February 07, 2019
The US District Court for the Western District of Pennsylvania entered into a consent decree of permanent injunction against Ranier’s Rx Laboratory Inc., a compounding facility.